Narrative
Full Description
Project narrative
On February 11, 2020, financial close was reached on a deal in which a syndicate of 34 banks — including Bank of China — entered into a $6.04 billion USD syndicated loan agreement with RPI 2019 Intermediate Finance Trust — a special-purpose financing vehicle established to acquire biopharmaceutical royalty interests, affiliated with Royalty Pharma, a U.S.-based royalty funder. The loan was divided into two tranches. AidData is tracking Tranche A-1, which carries a commitment amount of $3.2 billion USD and matures on February 11, 2025. The interest rate was LIBOR (1-month) plus 1%. The proceeds were used to repay amounts owed by RPI Intermediate Finance Trust under its existing senior secured credit agreement. The proceeds were used by the borrower to refinance existing debt — specifically to repay outstanding amounts owed by RPI Intermediate Finance Trust under its senior secured credit facility. This refinancing helped streamline the capital structure and support Royalty Pharma’s continued investments in pharmaceutical royalty assets. While Bank of China contributed to this loan (Record ID#), the following lenders also participated: Bank of America; Goldman Sachs Bank USA; JPMorgan Chase Bank, N.A.; Citibank, N.A.; Morgan Stanley Bank, N.A.; DNB Capital, LLC; TD Bank, N.A.; BBVA USA; The Bank of Nova Scotia; Truist Bank; PNC Bank, National Association; Bank of Montreal; UBS AG, Stamford Branch; The Huntington National Bank; Sumitomo Mitsui Banking Corporation; Regions Bank; Associated Bank N.A.; Hancock Whitney Bank; Siemens Financial Services, Inc.; Synovus Bank; Woodforest National Bank; The Bank of East Asia Limited, Los Angeles Branch; Taiwan Business Bank, Los Angeles Branch; Credit Industriel et Commercial, New York Branch; Flushing Bank; American Savings Bank, F.S.B.; First Hawaiian Bank; BankUnited, NA; TriState Capital Bank; Land Bank of Taiwan Los Angeles Branch; Mega International Commercial Bank Co., Ltd., New York Branch; CTBC Bank Co., Ltd.; and MidFirst Bank.
Staff comments
1. The entirety of the loan contract can be accessed at https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex102.htm The dropbox link for this loan contract can be accessed at https://www.dropbox.com/scl/fi/w6414wdlxzg5097nvtayf/Source_ID_217856.pdf?rlkey=t5njfib1im5hopidmrnfk6qq0&st=crkevbtj&dl=0 2. RPI 2019 Intermediate Finance Trust is a financing entity affiliated with Royalty Pharma, a U.S.-based firm that funds innovation in the life sciences sector by acquiring future royalty interests on biopharmaceutical products. 3. AidData estimates the interest rate by adding the 6-month average LIBOR rate in February 2020 and the stated margin of 1.00%. 4. The individual contributions of the 34 lenders to this $3.2 billion USD loan tranche are unknown. For the time being, AidData has estimated the contribution of Bank of China by assuming that each lender contributed an equal amount ($94,117,647.06 USD) to the Term A-1 tranche.